Champions Oncology Reports Resignation Of Director
HACKENSACK, N.J., Aug. 3, 2012 /PRNewswire via COMTEX/ -- Champions Oncology,
Inc. (OTC: CSBR), a company engaged in the development of advanced technology
solutions and services to personalize the development and use of oncology drugs,
today announced that James Martell has resigned from the Company's Board of
Directors. Mr. Martell, who started the company in 1985 as a sports-theme
restaurant franchise under the name "Champions Sports, Inc." and has remained on
the board through its conversion to a cancer technology company, has resigned to
pursue other business opportunities.
"Jim has been a valuable resource and advisor at Champions Oncology", commented
Joel Ackerman, Champions Oncology CEO. "We wish him much success in his new
endeavors."
About Champions Oncology, Inc. Champions Oncology, Inc. is engaged in the
development of advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's Tumorgraft Technology
Platform is a novel approach to personalizing cancer care based upon the
implantation of primary human tumors in immune deficient mice followed by
propagation of the resulting engraftments, or Tumorgrafts, in a manner that
preserves the biological characteristics of the original human tumor. The
Company uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology Solutions ("POS") in
which physicians and patients looking for information help guide the development
of personalized treatment plans, and Translational Oncology Solutions ("TOS") in
which pharmaceutical and biotech companies seeking personalized approaches to
drug development can lower the cost and increase the speed of developing new
drugs and increasing the adoption of existing drugs. The Company's Tumorgraft
Technology Platform consists of processes, physical tumors and information that
we use to personalize the development and use of oncology drugs. The Company is
building its Tumorgraft Technology Platform through the procurement, development
and characterization of numerous Tumorgrafts within each of several cancer
types. Tumorgrafts are procured through agreements with a number of institutions
in the U.S. and overseas as well as through its POS business. The Tumorgrafts
are developed and tested in the Company's laboratory facility in Baltimore,
Maryland.
Our POS business offers physicians and patients information to help guide the
development of personalized treatment plans. Our core offering utilizes our
technology platform to empirically test the response of a patient's tumor to
multiple oncology drugs or drug combinations. The process begins by implanting a
fresh fragment of the patient's tumor, typically received within 24 hours of
surgery or biopsy, in a small colony of immune-deficient mice to grow the tumor
tissue. This colony is then expanded by implanting the grown tumor tissue into
subsequent generations of mice until a sufficient number of mice are available
for testing. At that point, the colony is allocated to different groups, and
each mouse in a group is dosed with a different drug or drug combination. The
response of the tumor in each mouse is tracked over time and analyzed to
determine which drug or drug combination is providing the highest level of tumor
growth inhibition. Our data demonstrates that there is a high correlation
between the response to drugs of the tumor in mice with the response of the
tumor in the patient.
Contact:Susan J. Foreman410-369-0365
SOURCE Champions Oncology, Inc.
